# US 6,727,266 B2 · Substituted tryptophan derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,266 B2
- Document ID: US6727266B2
- Status: Granted
- Kind: B2
- Application number: 10/169,836
- Filed: 2002-07-10
- Published: 2003-07-10
- Granted: 2004-04-27
- Earliest claimed: 2000-01-26
- Assignees: Shionogi & Co., Ltd.
- Inventors: Fumihiko Watanabe
- Web page: https://patentgrep.com/patent/US6727266B2

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of the formula (I): wherein: R1 is represented by the formula: wherein R4, R5, R6, R7 and R8 are monovalent radicals such as: hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, nitro; non-aromatic heterocyclic group, and the like with certain provisos; Y is —OH or —NHOH; R2 is hydrogen, optionally substituted lower alkyl, or optionally substituted aralkyl; R3 is halogen, hydroxy, lower alkyloxy, or lower alkylthio; (b) n is an integer from 1 to 3; its optically active substance, its prodrug, its pharmaceutically acceptable salt, and its solvate.

## Claims

### Claim 1

A compound of the formula (I):
wherein R2 is hydrogen, optionally substituted lower alkyl, or optionally substituted aralkyl;
R3 is halogen, hydroxy, lower alkyloxy, or lower alkylthio;
n is an integer from 1 to 3;
R1 is represented by the formula:
wherein
R4 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro;
R5 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, nitro, or a non-aromatic heterocyclic group, provided that when R5 is amino substituted with two lower alkyls, R3 is not 6-methyloxy or 5-fluoro;
R6 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro,
provided that when R6 is lower alkyl, R3 is not 6-hydroxy or 6-lower alkyloxy;
R7 is halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro;
R8 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; and
Y is —OH or —NHOH,
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 2 (depends on 1)

A compound of claim 1, wherein R1 is a group represented by the formula:
wherein R4 is halogen,
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 3 (depends on 1)

A compound of claim 1, wherein R1 is a group represented by the formula:
wherein R5 is optionally substituted amino or a non-aromatic heterocyclic group,
provided that when R5 is amino substituted with two lower alkyls, R3 is not 6-methyloxy or 5-fluoro;
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 4 (depends on 1)

A compound of claim 1, wherein R1 is a group represented by the formula:
wherein R6 is a lower alkyl,
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 5 (depends on 1)

A compound of claim 1, wherein R1 is a group represented by the formula:
wherein R7 is lower alkyloxy,
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 6 (depends on 1)

A compound of claim 1, wherein R1 is a group represented by the formula:
wherein R8 is halogen,
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A compound of any one of claims 1 to 6, wherein R2 is hydrogen, its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A compound of any one of claims 1 to 6, wherein R3 is halogen, hydroxy, or lower alkyloxy and n is 1, its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition containing a compound of any one of claims 1 to 6 as an active ingredient.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

A method for treating a disease related with matrix metalloproteinase of a mammal, which comprises administration to said mammal of a compound of any one of claims 1 to 6 in a pharmaceutically effective amount.

### Claim 11 (depends on 1)

The compound of claim 1 wherein the non-aromatic heterocyclic group is pyrrolidinyl.

### Claim 12

A compound of the formula (I):
wherein R2 is hydrogen, optionally substituted lower alkyl, or optionally substituted aralkyl;
R3 is halogen, hydroxy, lower alkyloxy, or lower alkylthio;
n is an integer from 1 to 3;
R1 is represented by the formula:
wherein
R4 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro;
R5 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, nitro, provided that when R5 is amino substituted with two lower alkyls, R3 is not 6-methyloxy or 5-fluoro;
R6 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro,
provided that when R6 is lower alkyl, R3 is not 6-hydroxy or 6-lower alkyloxy;
R7 is halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro;
R8 is hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, or nitro; and
Y is —OH or —NHOH,
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.

### Claim 13

A compound of formula A1:
its optically active substance, its prodrug, its pharmaceutically acceptable salt, or its solvate.
